Methionine dependency describes the characteristic rapid in vitro death of most tumor cells in the absence of methionine. Combining chemotherapy with dietary methionine deprivation [methionine-deficient diet (MDD)] at tolerable levels has vast potential in tumor treatment; however, it is limited by MDD-induced toxicity during extended deprivation. Recent advances in imaging and irradiation delivery have created the field of stereotactic body radiotherapy (SBRT), where fewer large-dose fractions delivered in less time result in increased local-tumor control, which could be maximally synergistic with an MDD short course. Identification of the lowest effective methionine dietary intake not associated with toxicity will further enhance the cancer therapy potential. In this study, we investigated the effects of MDD and methioninerestricted diet (MRD) in primary and metastatic melanoma models in combination with radiotherapy (RT). In vitro, MDD dose-dependently sensitized mouse and human melanoma cell lines to RT. In vivo in mice, MDD substantially potentiated the effects of RT by a significant delay in tumor growth, in comparison with administering MDD or RT alone. The antitumor effects of an MDD/RT approach were due to effects on one-carbon metabolism, resulting in impaired methionine biotransformation via downregulation of Mat2a, which encodes methionine adenosyltransferase 2A. Furthermore, and probably most importantly, MDD and MRD substantially diminished metastatic potential; the antitumor MRD effects were not associated with toxicity to normal tissue. Our findings suggest that modulation of methionine intake holds substantial promise for use with short-course SBRT for cancer treatment.
Introduction
The ability of radiation therapy to effectively target and kill cancer cells may be enhanced by taking advantage of a simple, fundamental metabolic difference between normal and cancer cells in their requirement for exogenous methionine. Methionine is an essential amino acid indispensable for normal growth and development. It is needed for polyamine production; DNA, RNA and protein methylation; and glutathione synthesis (1) . Normal cells can thrive off the remethylation of homocysteine to methionine under conditions of methionine deficiency (MD), but most cancer cells are methionine auxotrophs, meaning they exhibit irreplaceable nutritional requirements for methionine (2) . Accumulating evidence demonstrates that, in the absence of methionine, cancer cells undergo cell cycle arrest followed by cell death [reviewed in (1) (2) (3) ] and that, during MD, cancer cells are more vulnerable to chemotherapeutic agents (4) (5) (6) (7) . Although it has been proposed that modulation of the methionine cycle may radiosensitize the tumor, this hypothesis has not yet been experimentally confirmed (8, 9) .
Clinical application of MD has been hindered by the toxicity that results from maintaining MD over the long duration typically required for cancer therapy. A methionine-deficient diet (MDD) results in substantial weight loss in cancer patients (0.5 kg/week) (10) . Further, methionine deprivation resulted in thrombocytopenia, neutropenia and hepatosteatosis in human studies of cancer and in in vivo rodent models of cancer (11) (12) (13) . However, recent advances in tumor imaging and irradiation techniques, along with the development of stereotactic body radiation therapy (SBRT), have begun to produce increased local-tumor control with a substantially shorter duration of radiation treatments compared with conventional fractionation (14) (15) (16) . This introduces a new horizon for clinical use of MDD because short-term MD is likely to be significantly less toxic to normal tissues.
Therefore, we aimed to investigate the potential synergistic effects of MDD with an SBRT-relevant dose in in vitro (human and mouse cell lines) and in vivo (mice) experimental models of highly metastatic melanoma. We chose to use melanoma as the model for this study because it is highly aggressive and is incurable when metastasized. Although previous results tended to reduce enthusiasm for radiation treatment of metastatic melanoma, this approach has begun to claim a role as a primary therapeutic option, mostly as a result of recent studies indicating improved results when higher doses (>5 Gy) are delivered to the tumor, which suggests that SBRT could be effective at higher doses per fraction (17) . Furthermore, the vast majority of MD studies investigated effects on primary tumors, so MD effects on metastasis remain unclear. Thus, the second goal of our study was to investigate the potential effects of MD on metastasis formation and development.
Materials and methods

Cell lines
B16-F10.1 (ATCC® CRL6475™, Nov 2016) and A375-MA1 (ATCC, CRL3222, Nov 2016) cells were used. Both cell lines, directly purchased from ATCC, Manassas, VA, were used within the first 6 months after purchase; only cells from two to four passages in the investigators' laboratories were used. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, 100 units/ml penicillin, 100 units/ml streptomycin, 2 mM glutamine, 10 mM HEPES and 1 mM sodium pyruvate in the presence of 5% CO 2 .
Wound healing (scratch) assay
Cells were seeded into six-well cell culture plates in DMEM medium (10% fetal bovine serum, 24 h, 37°C, 5% CO 2 ) and were cultured until they reached a 95% confluent monolayer. A linear wound in the layer of cultured cells was generated with a sterile 200 ml plastic pipette tip, and cells then were cultured in the medium containing either 0.2 mM (control), 0.02 mM or 0.002 mM methionine. For A375-MA1 cells, medium was changed every 24 h. Digital pictures were taken at hours 0, 3, 8 and 12 (B16-F10.1) and at 0, 18, 24 and 72 (A375-MA1) after creation of the scratches. The width of the scratch (expressed in pixels) was measured with Fiji software at each time interval and compared with the width of the scratch at baseline (i.e. 0 h, 0.2 mM methionine).
Clonogenic assay
Varying numbers of B16-F10.1 (2 × 10 2 -2 × 10 3 ) and A375-MA1 (2.5 × 10 2 -4 × 10 3 ) cells were plated in DMEM medium in six-well plates (in triplicate). After overnight incubation, cells were subjected to 0, 2.5, 7.5 or 10 Gy of X-rays (using a Faxitron X-ray cabinet model 43855F; Faxitron X-ray, Lincolnshire, IL). Immediately after exposure, medium was aspirated from all wells and cells were washed with phosphate-buffered saline. Methionine-free DMEM supplemented with dialyzed fetal bovine serum (4%, B16-F10.1; 6%, A375-MA1) and methionine [0.2 (control), 0.025 or 0.0025 mM] was added to relevant wells. For treatment groups that received the lowest concentration of methionine, the methionine concentration medium was increased to 0.2 mM after 48 h to facilitate colony formation for the remainder of the assay. Plates were incubated for 8 days (B16-F10.1) or 12 days (A375-MA1) to allow for colony formation. Colonies then were washed with saline and fixed for 10 min with 90% MeOH and 10% acetic acid, stained with 3% crystal violet for 1 h, and counted under a stereomicroscope. The plating efficiency for each treatment was calculated by dividing the number of colonies by the number of plated cells at the outset. The plating efficiencies of the irradiated cells then were normalized to those of non-irradiated (control) cells grown in each of the methionine conditions; the resulting surviving fractions were plotted.
Animal studies
Eight-week-old male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME). Animals were housed at the University of Arkansas for Medical Sciences animal facility under standardized conditions with controlled temperature and humidity and a 12 h light/dark cycle. For the primary tumor study, mice were randomly divided into four groups: animals fed methionine-adequate diet (MAD) (n = 6), animals fed MAD and subjected to local tumor treatment with ionizing radiation (IR) (n = 10), animals fed MDD (n = 6) and animals fed MDD and subjected to local IR (n = 10). The diets were purchased from Envigo (Madison, WI); details of contents are provided in Supplementary Table 1, available at Carcinogenesis Online. Total protein content of the two diets differed by less than 5%. On Day 0, all animals were inoculated with 5 × 10 5 syngenic B16-F10.1 melanoma cells via subcutaneous injection into the right hind limb.
Tumor sizes, body weights of mice and food and water consumption were measured every other day. Tumors were measured with calipers, and tumor volumes were calculated with the following formula: (L × W 2 )/2, where L is length in millimeter and W is width in millimeter. After the tumors grew 6-7 mm in diameter (MAD mice, Day 7; MDD mice, Day 10), animals were anesthetized with a mixture of xylazine (20 mg/kg) and ketamine (100 mg/kg) in 0.1 ml saline. Tumors were irradiated with 10 Gy of X-rays in a single dose (X-Rad 320 Biological Irradiator; Precision X-Ray, North Branford, CT) (320 kVp, 12.5 mA, 2 mm Al filter; 1.21 Gy/min dose rate).
Pulmonary metastasis was induced by injecting mice with 1 × 10 5 B16-F10.1 cells via the tail vein. In Experiment 1, mice were subjected to MAD, methionine-restricted diet (MRD) or MDD immediately after inoculation; mice were terminated 4 weeks after study initiation. In Experiment 2, pulmonary metastases were allowed to develop for 21 days, and mice then were subjected to MAD, MRD or MDD. Mice were observed daily and moribund animals were terminated.
Food and water were provided ad libitum throughout the study. Animals were killed by cervical dislocation; tumors, lungs, livers, kidneys, spleens and brains were excised and immediately fixed in 10% formaldehyde for histopathologic examination. A fraction of the tumor tissue was flash frozen in liquid nitrogen and stored at −80°C for molecular analysis. Metastases from the right lung were excised from the healthy tissue and were cryopreserved for RNA sequencing analysis or were fixed in 10% formaldehyde for histopathological evaluation. All procedures were performed according to the institutional and national guidelines for the care and use of animals and were approved by the University of Arkansas for Medical Sciences Institutional Animal Care and Use Committee (AUP# 3734). 
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Histopathologic evaluation
Hematoxylin and eosin tumor slides were scanned with Aperio ScanScope (Leica Biosystems, Richmond, IL), and the digital images were analyzed with Aperio ImageScope (Leica Biosystems). Slides were evaluated and subjectively scored for the presence of apoptotic and necrotic cells. Fivetier scoring was based on the amount of apoptotic or necrotic cells identified under light microscopy: none (0), minimal (1), mild (2), moderate (3) and severe (4) . Cumulative scores of apoptosis/necrosis for each of the 4 groups were calculated. The total area of each tumor and areas of geographic tumor necrosis were annotated manually by a surgical pathologist. Areas of cell injury and single necrotic cells were excluded from the analysis. Annotation layer analysis was performed, and percent necrosis was calculated by dividing the total area of geographic necrosis by the total area of the tumor.
Molecular and metabolic analyses
Details for the analysis of gene and protein expression, LINE-1 DNA methylation and determination of analytical components of methionine metabolism are provided in Supplementary Methods.
Statistical analysis
Statistically significant differences, resulting from comparing each treatment to the control (α = 95%), were assessed with one-way ANOVA followed by Dunnett's or Tukey's post hoc tests. Statistical analyses were performed with GraphPad Prism 6 (La Jolla, CA).
Results
Methionine deprivation negatively affects migratory capacity and clonogenicity of melanoma cell lines
To establish the direct effects of MD on tumor cells, we investigated the role of methionine in cell migration and clonogenicity in mouse (B16-F10.1) and human (A375-MA1) melanoma cells. In both cell lines, migratory capacity of the cells decreased when methionine concentration was reduced to 0.025 mM and 0.0025 mM (compared with 0.2 mM; P < 0.05) ( Figure 1A and B). In human melanoma cells (A375-MA1), cell death began after 72 h with 0.0025 mM methionine, resulting in a substantial decrease in wound closure.
For both cell lines, exposure to IR inhibited colony formation in a dose-dependent exponential fashion ( Figure 1C and D). Neither cell line was able to form colonies when cultured longterm in methionine-depleted medium, indicating methionine dependency (data not shown). Some evidence of reproductive capacity was observed at 0.0025 mM methionine in both cell lines; however, no colonies were viable by Day 7 after seeding. Lowering the methionine concentration for brief periods before and after IR exposure was associated with enhanced radiationinduced cell death in both cell lines (F 2,24 = 3.778, P = 0.0375 for B16-F10.1) and (F 6,24 = 11.49, P < 0.0001 for A375-MA1) ( Figure 1 ). These results indicated that even brief methionine deprivation sensitizes tumor cells to X-ray irradiation in vitro, which warranted further study in vivo.
MDD potentiates the effects of local-tumor irradiation in vivo
To investigate the role of methionine in radiosensitization of tumors, mice were inoculated subcutaneously in the hind limb with B16-F10.1 melanoma cells ( Figure 1E ), and effects of MDD diet were examined. Animals fed MAD had to be terminated on Day 17 due to expansive tumor growth; average relative tumor volume on Day 17 was 13.2-fold greater than on Day 7 ( Figure 1F ). Local-tumor irradiation with a single dose of 10 Gy on Day 7 significantly, but transiently, delayed tumor growth; rapid regrowth began on Day 15, and on Day 23, tumor volumes were 8.8-fold larger than on Day 7.
Feeding mice MDD without IR also significantly, but transiently, delayed tumor growth; on Day 23 relative tumor volume was 8.47-fold greater than on Day 10. However, combining MDD with IR resulted in profound effects. In the MDD/IR group, progressive tumor growth was not observed until Day 23, and on Day 35, the average relative tumor volume was only 5.7-fold greater than on Day 10. For 60% of the animals in the MDD/IR group, relative tumor volumes did not exceed 6-fold of the starting volume until sometime between Days 38 and 44 ( Figure 1F ).
Radiotherapy-potentiated effects of MDD on tumor growth are not due to increased necrosis and apoptosis or to alterations in DNA methylation
Previous studies indicated that MDD activates apoptotic responses in the tumor and that radiation causes necrotic effects (7). Furthermore, both MDD and radiation are known to affect DNA methylation (8, 18) . Therefore, we investigated these endpoints in induced B16-F10. Expression of 84 genes involved in necrotic and apoptotic responses was examined in tumors, and results from the MAD group were compared with those from the MAD/IR and MDD/ IR groups. Despite substantial differences in treatment regimens, only a small subset of genes was differentially regulated (Supplementary Figure 1D , Supplementary Table 2, available at Carcinogenesis Online). Among these, the increased expression of Glul and Pygl genes, which interact with RIPK3, was of particular interest. Specifically, Glul expression in MDD/IR tumors was 1.9-fold higher than in MAD tumors (P < 0.01); Pygl expression in MAD/IR and MDD/IR tumors was 1.8-and 2.5-fold, respectively, higher than in MAD tumors (P < 0.01). However, the small number of differentially regulated genes and generally low magnitude of changes in expression warranted further investigation of the primary mechanisms of MDD/IR-induced suppression of tumor growth.
DNA methylation is a key epigenetic mechanism that governs normal cellular homeostasis (19) , and virtually all human cancers and numerous experimental cancer models are characterized by the loss of global DNA methylation that predetermines an overall tumor hypomethylative phenotype and stems primarily from the repetitive elements (20) . Because methionine is a major substrate for S-adenosylmethionine (SAM)-a universal donor of methyl groups for DNA methylation-we hypothesized that MD may trigger gross alterations in DNA methylation. Because LINE-1 is the most abundant repetitive element (21), mouse LINE-1 elements were examined for changes in methylation status. We chose six LINE-1 elements that belong to the most abundant 'A'-type promoter and that are characterized by different evolutionary ages (22) . Mice in the MDD group had hypermethylation of most LINE-1 elements, but mice in the MAD/IR group displayed DNA hypomethylation, especially in L1MdA_VI and VII elements, which reached an almost 2-fold decrease (P < 0.05) (Supplementary Figure 1E , available at Carcinogenesis Online). At the same time, mice in the MDD/IR group did not have any consistent alterations in DNA methylation of LINE-1.
Potentiation of tumor-growth inhibition by targeting Mat2a in combination with MDD
Because methionine is a crucial molecule in one-carbon metabolism (Figure 2A) , we analyzed metabolites of the methionine cycle. Treatment with only local irradiation resulted in a nearly 2-fold decrease in methionine concentrations within tumors, but feeding mice MDD alone or combined with irradiation resulted in nearly an 8-fold decrease (Table 1 ). There were no substantial changes in other metabolites of the methionine cycle, except for a 1.7-fold increase in oxidized glutathione concentrations in tumor tissues of mice in the MDD/IR group.
Further, we analyzed expression of genes encoding proteins that are involved in the methionine cycle. Tumor tissues of the MDD group had increased expression of Mat2a, Mthfr and Gclm (P < 0.05) ( Figure 2B) ; the most pronounced changes were in expression of Mat2a (2.8-fold, P < 0.05), which is critical for the first step of extrahepatic methionine biotransformation and is upregulated in tumors (23) (24) (25) . Subjecting the tumors to local IR resulted in attenuated expression of Mat2a, as well as Mthfr and Gclm ( Figure 2B ). We then evaluated the potential for a pharmacological inhibitor of Mat2a [fluorinated N,N-dialkylaminostilbene-5 (FIDAS-5)] to potentiate the effects of cancer therapy ( Figure 2C ). FIDAS-5 recently was reported to repress colon cancer in in vitro and in vivo settings (26) . In response to eight consecutive days of FIDAS-5 gavage combined with MDD, rapid tumor progression halted. On the other hand, no inhibiting effects on tumor growth were observed when FIDAS-5 was administered without MDD, including its combination with IR ( Figure 2D ). These findings suggest that, when combined with MDD, IR downregulates expression of Mat2a (encoding the major methionine adenosyltransferase) and halts methionine biotransformation, leading to substantially decreased tumor progression rates.
Dietary restriction of methionine decreases tumor metastatic potential
B16-F10.1 cells are highly metastatic and readily cause pulmonary metastasis as early as 3-4 weeks after subcutaneous injection (27) . In our initial study, only one mouse, in the MDD/IR group, developed a well-formed metastasis. The metastasis was confined within the pulmonary vein and showed no evidence of extravasation ( Figure 3A) . No metastases were detected in the lungs, livers, kidneys, spleens or brains of the remaining nine animals in that treatment group. To investigate the role of methionine in metastasis formation, mice were injected i.v. (via the tail vein) with B16-F10.1 cells and were subjected either to MAD, MDD or MRD (25% of the methionine content in MAD). After 4 weeks (time for pulmonary metastasis to develop), mice were terminated and the lungs were removed. The number of surface pulmonary metastases was substantially lower for the MRD and MDD groups than for the MAD group (MAD, 42; MRD, 7; MDD, 4; P < 0.001) ( Figure 3B and C). Histopathological evaluation confirmed widely disseminated metastases throughout the lungs of mice in the MAD group, an isolated single metastasis in the MRD group and only microscopically identifiable metastasis in the MDD group. (Figure 3D ).
Dietary methionine restriction affects established metastatic lesions and increases survival
Having observed substantial decreases in the metastatic potential of B16-F10.1 cells in response to methionine deprivation, we investigated the effects of methionine deprivation on already formed metastasis. Three weeks after i.v. injection of B16-F10.1 cells, established metastases were confirmed with histological examinations of lung tissue sections, which were performed weekly on three randomly selected mice. Surviving mice then were fed either MAD, MRD or MDD. All mice in the MAD group expired by Day 32 ( Figure 3E ). However, 60% of mice in the MDD group and 80% of mice in the MRD group were alive by Day 35. Similar to the earlier findings, gross and histopathological examinations (data not shown) revealed widely disseminated lungs metastases in the MAD group but only isolated lung metastases in the mice that survived until Day 35.
MDD and MRD lead to overlapping gene expression changes in metastases
To identify the molecular mechanisms underpinning the changes in metastatic efficiency observed with MDD and MRD, we performed RNA sequencing on tissue samples of excised B16-F10.1 lung metastases. To identify differentially regulated transcripts, we selected those for which the false discovery rate was below 0.05. In the MDD group, 59 transcripts were differentially regulated; in the MRD group, 75 transcripts were differentially regulated. Twenty-two transcripts were common to both MDD and MRD groups, and the expression change was always in the same direction in both groups (i.e. upregulated or downregulated; Figure 4A and B). In both groups, we observed enrichment for the Gene Ontology (GO) terms 'response to peptide hormone', 'response to cytokine' and negative regulation of peptidase activity' in comparison with the MAD group ( Figure 4C ). The effect was largely driven by decreased expression of members of the serine protease inhibitor (serpin) superfamily, particularly Serpina1a, Serpina1b and Serpina3k. In all cases, expression was more than 7-fold lower than that of the MAD group ( Figure 4C ). The GO term 'immune system process' also was significantly enriched in both groups. The only common gene associated with this GO term was fibrinogen beta chain, which was strongly downregulated in both MDD and MRD groups. Gene expression of selective targets was confirmed using quantitative real-time PCR (Supplementary Figure 2, available at Carcinogenesis Online).
In both MDD and MRD groups, the term 'cell-cell adhesion' was significantly enriched. Some transcripts for the related genes Eif4g1 (ENSMUST00000115463) and Plec (ENSMUST00000074834) were upregulated by more than 10-fold in both groups. The related GO term 'cell adhesion' also was significantly enriched in the non-isoform analysis for the MRD group (P = 0.012) and nearly reached significance in the MDD group (P = 0.08); 'single organismal cell-cell adhesion' was significantly enriched in the MDD group (P = 0.02). Levels of the transcripts for Cd93 and Hapln1 increased and decreased, respectively. In contrast to results seen in primary tumors, neither MDD nor MRD affected expression of Mat2a, Mthfr and Gclm. These findings were confirmed by the analysis of the critical components of the methionine cycle, where MRD did not result in decreases of even intrametastatic methionine concentrations (Table 1) .
Continued MDD, but not MRD, leads to normal tissue toxicity
In the initial study, negative trends in the body weights of mice fed MDD were observed ( Figure 5A ). The body weight curves were especially steep during the first days of MDD, when animals lost ~17% of their body weights. However, progression of weight loss decreased after Day 7, and body weights were stabilized in MDD/IR mice on approximately Day 23, when a decrease of ~32% in body weight was noted. These results agree with the previous life-long study in which the body weights of mice fed MDD averaged ~65% of control weight (28) .
Overall food consumption in mice fed MDD was lower than in those fed MAD; the ratio of consumed food/body weight was nearly the same in all groups of mice. Water consumption did not significantly differ among the three groups (Supplementary Figure 3 , available at Carcinogenesis Online). Histopathological evaluation revealed evidence of steatosis in the livers of mice in the MDD/IR group that were terminated after Day 38 ( Figure 5B ). In the metastatic studies, feeding mice MRD did not negatively affect body weights ( Figure 5C ), but MDD did. Further, no evidence of liver steatosis was observed in mice fed MRD regardless of the duration ( Figure 5D ).
Discussion
Previous studies convincingly demonstrated that MDD significantly enhances the effects of chemotherapy (1-5, 7) . At the same time, to the best of our knowledge, no studies have explored the potential advantage of combining MDD or MRD with radiation therapy. In this study, we demonstrated that modulating the dietary intake of methionine holds tremendous potential for controlling growth of both primary and metastatic tumors, and it has synergistic effects with IR in in vitro and in vivo models of melanoma.
Initial in vitro studies clearly demonstrated that MD enhances the ability of IR to kill tumor cells. The observed effect was dose-dependent and resembled persistence: In our experimental system, survival of tumor cells after IR was significantly lower for tumor cells grown on MD medium than on methionine-adequate medium, even after methionine replenishment. These findings suggest that the required duration of MD in the clinic may potentially be even shorter than the interval between fractions of radiotherapy.
In in vivo settings, feeding mice MDD alone was nearly as potent in suppressing tumor growth as was local exposure of the tumor to 10 Gy of X-rays, and combining MDD with IR resulted in the most substantial suppressive effects on tumor growth. These findings are consistent with the previous report on the combined effects of MDD with chloroethylnitrosourea in the same B16-F10 experimental system (5). In the latter study, however, the experiment was terminated on Day 33, a time point at which, in our experimental system, tumor regrowth had just started in some animals. The MDD-induced potential for inhibiting tumor growth seems to be more potent than other approaches of radiosensitization or radiation enhancement. For instance, we and others observed only several days' delay of tumor growth in B16-F10 tumors after combining IR [local irradiation with conventional fractionation (2 Gy)] with hyperthermia and (29, 30) or after treatment with angiogenesis inhibitors (31) . Analysis of the critical components of one-carbon metabolism revealed substantial alterations in concentrations of methionine and glutathione in tumor tissues. Further, gene expression analyses demonstrated that the potent antitumorigenic effects of the combined MDD/IR treatment is achieved via downregulation of Mat2a. This gene not only is an important facilitator of methionine biotransformation in extrahepatic tissues but also is upregulated in human tumors (23) (24) (25) . Further increases in Mat2a expression in the tumor that were observed after MDD administration may be explained by the tumor's attempt to compensate for the lack of the metabolites (for which methionine serves as a critical substrate) by increased biotransformation of methionine. IR, however, when combined with MDD, substantially decreases expression of Mat2a, depriving the tumor of the critical components of one-carbon metabolism. These findings further support the hypothesis that targeting methionine biosynthesis via Mat2a is a promising avenue in cancer therapy (32) .
Another important finding of this study is the potent antimetastatic potential of methionine deprivation. The single metastasis observed in the pulmonary vein of mice given MDD during tumor progression was confined to the blood vessel, and despite its large size, was not able to extravasate. This may be due to decreased invasive properties that cancerous cells must give up in exchange for fulfilling their methionine requirements (2) . Future studies addressing this phenomenon are highly warranted because the metastatic activity of melanoma and many other cancers dictate patient survival and quality of life.
Upregulated expression of Mat2a in the primary tumors was not affected during metastasis, suggesting involvement of principally different anticancer mechanisms exerted by methionine restriction. The RNA sequencing analysis revealed involvement of the immune system in the metastasis differential response to methionine deprivation. Of particular interest was a substantial decrease in expression of several members of the serpin superfamily. Clade A serpin genes that were affected by both MRD and MDD are protease inhibitors that target proteins such as trypsin, plasmin, thrombin and elastase, and are tightly involved in inflammation and complement activation (33) (34) (35) ; however, their roles in cancer and metastasis are not clear. Recent studies indicate that clade A serpins are highly expressed in tumors where they inhibit serine proteases in response to inflammatory markers such as cytokines. Serpina1a (SERPINA1 in humans; also known as α1-antitrypsin) has been shown to regulate processes such as migration and invasion in human cancers (36) , and the alterations in gene expression seen in the RNA sequencing assay may be linked to the observed decreased metastatic potential that resulted from MDD and MRD. Serpina3k is a member of a cluster of 14 murine genes that correspond to human SERPINA3 (also known as α1-antichymotrypsin), which forms a complex with prostate-specific antigen in the plasma of patients with prostate cancer (37) .
Decreases in body weight observed in mice fed MDD are in line with effects observed in previous studies (28) . It is worth mentioning that, in our study, mice were observed for up to 47 days after initiation of MDD administration, but the time expected for a full course of SBRT is much shorter (on the order of 21 days or less). Furthermore, mice rapidly regained weight after returning to the normal diet (5) . At the same time, our studies with pulmonary metastasis showed that decreases in the recommended daily dietary intake of methionine have a tremendous effect on development or progression of metastasis without loss in body weight or evidence of liver toxicity.
Future studies in other model systems clearly are needed to investigate the potential use of transient, well-timed MDD in combination with radiation therapy for cancer therapy. A vegan diet would be an example of 'reduced' methionine intake and, therefore, dietary requirements to achieve potent antitumor results are clearly feasible. Regardless, the exact windows of tumor susceptibility to MDD need to be established in in vivo models to refine the possible dietary scenarios that would result in maximal antitumor effects; such studies are underway in our laboratories.
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